Cytek Biosciences Inc reports results for the quarter ended September 30 - Earnings Summary

Cytek Biosciences Inc reported a quarterly adjusted loss of 4 cents per share for the quarter ended September 30, an improvement from a loss of 1 cent per share in the same quarter last year. Revenue increased by 1.5% to $52.29 million, surpassing analyst expectations of $51.49 million. The company's shares rose 12.7% this quarter but are down 39.8% year-to-date. Analysts maintain a "buy" rating, with a median 12-month price target of $4.25, slightly above the last closing price of $4.01.